Introduction. Antibodies to human leukocyte antigens (HLA) are one of the major immune barriers to successful organ transplantation. In addition to complementdependent cytotoxicity (CDC) assay as a standard method for the HLA antibodies detection, more sensitive solid-phase assays like Luminex were introduced. The aim of this study was to define mean fluorescence intensity (MFI) cutoff values of HLA Class I antibodies detected by Luminex from those detected by CDC given the possibility to use only Luminex assay in HLA antibody screening. Methods. This is a retrospective analysis of the HLA antibody screening results of patients on a kidney transplant waiting list, performed at the Tissue Typing Laboratory, Clinical Hospital Center Ri...
Background. This study evaluated the influence of circulating anti-HLA antibodies on outcomes of 97 ...
Background: Two of the most sensitive methods for detecting donor-specific HLA antibodies (DSAs) are...
International audienceBackground. Defining the clinical relevance of donor-specific HLA antibodies (...
Introduction. Antibodies to human leukocyte antigens (HLA) are one of the major immune barriers to ...
The introduction of more sensitive techniques, such as Luminex® for HLA antibody screening of patien...
The recent introduction of new technologies such as Luminex has provided alternative methods to the ...
Background: The aim of this study was to determine the frequency of exposure to different sensitizin...
B-cell crossmatch (BXM) was originally introduced to increase the sensitivity to detect anti-HLA ant...
Objectives: For decades, the detection of anti-HLA antibodies in candidates for solid-organ transpla...
Background. HLA-specific antibodies detected by solid phase assays are increasingly used to define u...
Objectives: The relevance of anti-HLA antibodies in patients awaiting kidney transplants is well rec...
Background. Allospecific anti-HLA antibodies (Abs) are associated with rejection of solid organ graf...
Cilj istraživanja: Protutijela HLA u serumu bolesnika na Listi ĉekanja za transplantaciju bubrega mo...
Luminex single antigen bead assays revolutionized human leukocyte antigen (HLA) antibody detection o...
The number and the binding affinity, measured as the mean fluorescent intensity (MFI) of HLA-specifi...
Background. This study evaluated the influence of circulating anti-HLA antibodies on outcomes of 97 ...
Background: Two of the most sensitive methods for detecting donor-specific HLA antibodies (DSAs) are...
International audienceBackground. Defining the clinical relevance of donor-specific HLA antibodies (...
Introduction. Antibodies to human leukocyte antigens (HLA) are one of the major immune barriers to ...
The introduction of more sensitive techniques, such as Luminex® for HLA antibody screening of patien...
The recent introduction of new technologies such as Luminex has provided alternative methods to the ...
Background: The aim of this study was to determine the frequency of exposure to different sensitizin...
B-cell crossmatch (BXM) was originally introduced to increase the sensitivity to detect anti-HLA ant...
Objectives: For decades, the detection of anti-HLA antibodies in candidates for solid-organ transpla...
Background. HLA-specific antibodies detected by solid phase assays are increasingly used to define u...
Objectives: The relevance of anti-HLA antibodies in patients awaiting kidney transplants is well rec...
Background. Allospecific anti-HLA antibodies (Abs) are associated with rejection of solid organ graf...
Cilj istraživanja: Protutijela HLA u serumu bolesnika na Listi ĉekanja za transplantaciju bubrega mo...
Luminex single antigen bead assays revolutionized human leukocyte antigen (HLA) antibody detection o...
The number and the binding affinity, measured as the mean fluorescent intensity (MFI) of HLA-specifi...
Background. This study evaluated the influence of circulating anti-HLA antibodies on outcomes of 97 ...
Background: Two of the most sensitive methods for detecting donor-specific HLA antibodies (DSAs) are...
International audienceBackground. Defining the clinical relevance of donor-specific HLA antibodies (...